Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777276 | 0.80 | MGAM (0.47) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL3777279 | 0.80 | MGAM (0.47) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL15698708 | 0.80 | MGAM (0.47) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL8719877 | 0.76 | MGAM (0.50) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL1419495 | 0.73 | CYP2C9 (0.56) | GAASMN1; SMN2ALDH1A1TSHRCYP2C9 | |
| SCHEMBL4661706 | 0.73 | GAA (0.47) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL1419493 | 0.73 | CYP2C9 (0.56) | GAASMN1; SMN2ALDH1A1TSHRCYP2C9 | |
| SCHEMBL14507426 | 0.69 | GAA (0.50) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL14232717 | 0.69 | GAA (0.61) | MGAMGAASIMGAM2SMN1; SMN2 | |
| SCHEMBL3968607 | 0.69 | MGAM (0.36) | MGAMGAASIMGAM2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007127309-A2 | PROCESSES FOR THE SYNTHESIS OF 3-ISOBUTYLGLUTARIC ACID | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-08 | — | — | WO | disclosed |
| US-20070259917-A1 | Processes for the synthesis of 3-isobutylglutaric acid | TEVA PHARMACEUTICALS USA, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259917-A1 | Processes for the synthesis of 3-isobutylglutaric acid | TEVA PHARMACEUTICALS USA, INC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259917-A1 | Processes for the synthesis of 3-isobutylglutaric acid | OGDH, GLUL, PGD | MGAM 256/4885GAA 314/4885SI 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.